Skip to main content Skip to main navigation menu Skip to site footer

Role of platelet count, platelet indices, and immature platelet fraction as potential markers for monitoring platelet reactivity in patients with acute coronary syndrome undergoing percutaneous coronary intervention

  • Ikke Nanda Amalia ,
  • Yetti Hernaningsih ,
  • Puspa Wardhani ,

Abstract

The acute coronary syndrome is an acute manifestation of coronary heart disease, which is caused by a ruptured plaque of the coronary artery, thus forming a thrombus formation and resulting in myocardial infarction. Reperfusion therapy in patients with acute coronary syndrome is needed with the aim of preventing the area myocardium from experiencing necrosis by percutaneous coronary intervention using a stent, but this action may be caused by stent re-stenosis, bleeding, or thrombosis. Treatment with dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention is recommended for used to prevent stent restenosis events or bleeding. A combination of aspirin and P2Y12 inhibitors is commonly used, such as thienopyridine-like clopidogrel and prasugrel as well as non-thienopyridine class drugs to reduce the thrombosis formation. Monitoring DAPT after PCI requires monitoring the reactivity platelet by platelet aggregation test, but this examination is rarely carried out because it needs special tools and a fairly expensive inductor. Another marker that is less noticeable is the platelet marker by complete blood count (CBC), which uses a hematology analyzer such as platelet count, which decreases and indicates bleeding. Index platelets (PDW, P-LCR, MPV, and PCT) reflect that platelet reactivity indicators and immature platelet fraction shows the proportion of thrombopoiesis. This review provides a summary of ACS (Definition, classification, and pathophysiology), PCI (Definition, clinical indication, characteristics of stent and complication of PCI), Combination of dual antiplatelet therapy and Platelet measure for monitoring ACS after PCI (Platelet count, index platelets like PDW, P-LCR, MPV, PCT and immature platelet fraction).

References

  1. World Health Organization. Cardiovascular diseases (CVDs) 2021 [Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
  2. Kimura K, Kimura T, Ishihara M, Nakagawa Y, Nakao K, Miyauchi K, et al. JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome. Circulation Journal. 2019;83(5):1085-196.
  3. Bergmark BA, Mathenge N, Merlini PA, Lawrence-Wright MB, Giugliano RP. Acute coronary syndromes. The Lancet. 2022;399(10332):1347-58.
  4. Vogel B, Claessen BE, Arnold SV, Chan D, Cohen DJ, Giannitsis E, et al. ST-segment elevation myocardial infarction. Nature reviews Disease primers. 2019;5(1):39.
  5. Atwood J. Management of Acute Coronary Syndrome. Emergency Medicine Clinics. 2022;40(4):693-706.
  6. Song X, Song J, Shao M, Gao X, Ji F, Tian H, et al. Depression predicts the risk of adverse events after percutaneous coronary intervention: a meta-analysis. Journal of Affective Disorders. 2020;266:158-64.
  7. Sharma SK, Bolduan RW, Patel MR, Martinsen BJ, Azemi T, Giugliano G, et al. Impact of calcification on percutaneous coronary intervention: MACE‐Trial 1‐year results. Catheterization and Cardiovascular Interventions. 2019;94(2):187-94.
  8. Natsuaki M, Morimoto T, Shiomi H, Yamamoto K, Yamaji K, Watanabe H, et al. Bleeding Outcomes After Percutaneous Coronary Intervention in the Past Two Decades in Japan―From the CREDO-Kyoto Registry Cohort-2 and Cohort-3―. Circulation Journal. 2022;86(5):748-59.
  9. Chang M, Park D-W. Optimal duration of dual antiplatelet therapy after implantation of drug-eluting stents: shorter or longer? Cardiology and Therapy. 2014;3:1-12.
  10. Oktaviono YH. Kompilasi Pada Intervensi Koroner Perkutan. Airlangga University Press; 2020.
  11. Verdoia M, Sartori C, Pergolini P, Nardin M, Rolla R, Barbieri L, et al. Immature platelet fraction and high-on treatment platelet reactivity with ticagrelor in patients with acute coronary syndromes. Journal of thrombosis and thrombolysis. 2016;41:663-70.
  12. Thomas MR, Storey RF. Clinical significance of residual platelet reactivity in patients treated with platelet P2Y12 inhibitors. Vascular pharmacology. 2016;84:25-7.
  13. Setiawati M, Adhipireno P. Perbedaan Fungsi Agregasi Trombosit, MPV, Dan Rasio MPV/PC Pada Pasien Stroke Iskemik dan Stroke Hemoragik. Medica Hospitalia: Journal of Clinical Medicine. 2018;5(1).
  14. Mappangara I, Mappahya AA, Witjaksono S. The Comparative and Usefulness of Platelet Distribution Width in Acute Coronary Syndrome. The Indonesian Biomedical Journal. 2016;8(3):173-8.
  15. Smit M, Coetzee A, Lochner A. The pathophysiology of myocardial ischemia and perioperative myocardial infarction. Journal of Cardiothoracic and Vascular Anesthesia. 2020;34(9):2501-12.
  16. Yuan D, Chu J, Qian J, Lin H, Zhu G, Chen F, et al. New Concepts on the Pathophysiology of Acute Coronary Syndrome. Reviews in Cardiovascular Medicine. 2023;24(4):112.
  17. Sugiyama T, Yamamoto E, Fracassi F, Lee H, Yonetsu T, Kakuta T, et al. Calcified plaques in patients with acute coronary syndromes. Cardiovascular Interventions. 2019;12(6):531-40.
  18. Indriastuti E, Hernaningsih Y, Indrasari YN. Immature Platelet Fraction as A Potential Marker To Differentiate Types of Acute Coronary Syndrome. Indonesian Journal of Clinical Pathology and Medical Laboratory. 2020;27(1):16-21.
  19. Barstow C, Rice M, McDivitt JD. Acute coronary syndrome: diagnostic evaluation. American family physician. 2017;95(3):170-7.
  20. Libby P, Pasterkamp G, Crea F, Jang I-K. Reassessing the mechanisms of acute coronary syndromes: the “vulnerable plaque” and superficial erosion. Circulation research. 2019;124(1):150-60.
  21. Suryawan IGR. BUKU AJAR SINDROM KORONER AKUT: Airlangga University Press; 2023.
  22. Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circulation research. 2014;114(12):1852-66.
  23. Eisen A, Giugliano RP, Braunwald E. Updates on acute coronary syndrome: a review. JAMA cardiology. 2016;1(6):718-30.
  24. Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European heart journal. 2021;42(14):1289-367.
  25. Wang P, Zhang S, Zhang K, Tian J. Frailty predicts poor prognosis of patients after percutaneous coronary intervention: a meta-analysis of cohort studies. Frontiers in Medicine. 2021;8:696153.
  26. Hoole SP, Bambrough P. Recent advances in percutaneous coronary intervention. Heart. 2020.
  27. Giustino G, Colombo A, Camaj A, Yasumura K, Mehran R, Stone GW, et al. Coronary in-stent restenosis: JACC state-of-the-art review. Journal of the American College of Cardiology. 2022;80(4):348-72.
  28. Mathew E. Implementation of an Anti-Platelet Medication Education Process and Post-Discharge Motivational Phone Calls for Post Cardiac Stent Patients: Brandman University; 2017.
  29. Patti G, Micieli G, Cimminiello C, Bolognese L. The role of clopidogrel in 2020: a reappraisal. Cardiovascular therapeutics. 2020;2020.
  30. Costa F, Montalto C, Branca M, Hong S-J, Watanabe H, Franzone A, et al. Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: A meta-analysis of randomized trials. European Heart Journal. 2023;44(11):954-68.
  31. Galli M, Capodanno D, Benenati S, D’Amario D, Crea F, Andreotti F, et al. Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials. European Heart Journal-Cardiovascular Pharmacotherapy. 2022;8(5):519-28.
  32. Kang J, Rizas KD, Park KW, Chung J, van den Broek W, Claassens DM, et al. Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis. European Heart Journal. 2023;44(15):1360-70.
  33. Laine M, Panagides V, Frère C, Cuisset T, Gouarne C, Jouve B, et al. Platelet reactivity inhibition following ticagrelor loading dose in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Journal of Thrombosis and Haemostasis. 2019;17(12):2188-95.
  34. Wang D, Yang X-H, Zhang J-D, Li R-B, Jia M, Cui X-R. Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis. BMC cardiovascular disorders. 2018;18(1):1-7.
  35. Saputra A, Hernaningsih Y, Wardhani P. Correlation Between Platelet Aggregation Test With Maximum Amplitude Of Thromboelastography (Ma-Teg) Parameters In Covid-19 Patients At Rsu Dr. Soetomo Surabaya In Assessing The Function Of Platelet. Journal of Pharmaceutical Negative Results. 2023:25-31.
  36. Roshal M, Gil MR. Measurement of platelet count, mean platelet volume, and reticulated platelets. Transfusion medicine and hemostasis: Elsevier; 2019. p. 811-5.
  37. Bath P, Algert C, Chapman N, Neal B. Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke. 2004;35(3):622-6.
  38. Marrocco I, Altieri F, Peluso I. Measurement and clinical significance of biomarkers of oxidative stress in humans. Oxidative medicine and cellular longevity. 2017;2017.
  39. Keerthy Aberna A. Role of Platelet Indices in Differentiating the Causes of Thrombocytopenia in a Tertiary Care Hospital: Madras Medical College, Chennai; 2019.
  40. Gul M, Uyarel H, Akgul O, Akkaya E, Surgit O, Cakmak HA, et al. Long-term prognostic significance of admission plateletcrit values in patients with non-ST elevation myocardial infarction. Blood Coagulation & Fibrinolysis. 2016;27(6):696-701.

How to Cite

Amalia, I. N., Hernaningsih, Y. ., & Wardhani, P. . (2024). Role of platelet count, platelet indices, and immature platelet fraction as potential markers for monitoring platelet reactivity in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Bali Medical Journal, 13(2), 582–586. https://doi.org/10.15562/bmj.v13i2.5133

HTML
4

Total
2

Share

Search Panel

Ikke Nanda Amalia
Google Scholar
Pubmed
BMJ Journal


Yetti Hernaningsih
Google Scholar
Pubmed
BMJ Journal


Puspa Wardhani
Google Scholar
Pubmed
BMJ Journal